Pamplona Therapeutics and Coherent Biopharma today announced a strategic collaboration to combine Pamplona's AI-driven targeted protein degradation (TPD) molecular design capabilities with Coherent's dual-target conjugation technologies, Bi-XDC and C-PROTAC.

Pamplona Therapeutics today announced that its first-in-class targeted protein degrader for the treatment of autoimmune diseases has received clearance from the U.S. Food and Drug Administration (FDA).